MedTrace Logo

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

NCT00614653 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2016-08-01

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.

Conditions

Interventions

DRUG

Bevacizumab

5 mg/kg IV Over 90 Minutes Every 2 Weeks

DRUG

Erlotinib

100 mg by mouth Once Daily on days with radiation.

DRUG

Capecitabine

400 mg/m\^2 PO Twice Daily on days with radiation.

RADIATION

Radiation Therapy

Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Sunil Krishnan, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00614653 on ClinicalTrials.gov